In the fast-paced world of biotechnology, MarketWatch Automation leverages world-class data from Dow Jones and FactSet to deliver cutting-edge content swiftly and accurately. Partnering with Automated Insights, MarketWatch Automation ensures you receive the latest updates with unparalleled precision, revolutionizing the way biotech data is accessed and analyzed. With a focus on AstraZeneca and other key […]
Category: AstraZeneca
EU Approval for AstraZeneca Calquence Regimens in CLL
The European Union (EU) has granted approval to AstraZeneca’s Calquence-based regimens for the treatment of previously untreated chronic lymphocytic leukaemia (CLL) in adults. The endorsement comes on the heels of impressive results from the AMPLIFY Phase III trial, which underscored the efficacy of these novel treatments in CLL management. Calquence, medically known as acalabrutinib, is […]
Europe Approves AstraZeneca’s Calquence Combo for CLL
Europe has given its approval to AstraZeneca’s fixed-duration Calquence combination for the treatment of chronic lymphocytic leukemia (CLL), a type of cancer that is often slow-growing but can become harder to treat over time. This decision, backed by a positive opinion from the European Medicines Agency’s (EMA) scientific panel, is fueled by compelling data from […]
EC Approval for AstraZeneca’s Calquence in CLL Treatment
Chronic lymphocytic leukaemia (CLL) is the most prevalent form of leukaemia in adults, with an estimated 27,000 cases diagnosed in key European countries in 2024. Despite being deemed incurable, patients often endure prolonged treatment, such as AstraZeneca’s Calquence, which has now received approval from the European Commission for first-line use against CLL. This development marks […]
